The FDA has approved GlaxoSmithKline's (GSK) Tafinlar and Mekinist drugs for treating melanoma...

|About: GlaxoSmithKline (GSK)|By:, SA News Editor

The FDA has approved GlaxoSmithKline's (GSK) Tafinlar and Mekinist drugs for treating melanoma that has spread or can't be surgically removed. The drugs, which are aimed at patients with certain gene mutations, are expected to generate annual sales of $622M by 2016, and will compete with Roche's (RHHBY.OB) Zelboraf and Bristol-Myers Squibb's (BMY) Yervoy. GSK's shares -0.4% in London. (PR)